First Time in Israel - International Patients Can Participate in Rambam Hospital's Clinical Trials
Rambam Medical Center has received worldwide recognition as one of the leading institutions specializing in the study and treatment of cancerous tumors. International clinical studies are conducted in the Oncology and Hematology Center's laboratories.
Participation in such studies provides patients with a unique opportunity to receive oncological treatment FREE OF CHARGE and take advantage of the most innovative methods.
The patient's ability to take part in the trials depends on the nature of cancerous cells, the condition's phase, the patient's previously received treatment, and his or her general health.
All clinical trials comply with medical ethics and safety and security regulations. The patients are under constant care of our doctors and the trials are run in accordance with the Helsinki Declaration. All projects involving volunteers are monitored according the standards of Good Clinical Practice (GCP), a set of rules that protects human rights and ensures compliance with ethical standards
Rambam conducts clinical studies for almost all types of tumors.
| Cancer type | Clinical trial |
|---|---|
| Soft tissue sarcoma 0516-16 | A phase 1b/phase 2. Study evaluating Gemcitabine and Docetaxel with or without Olaratumab |
| Tumors of pancreatic, Gastrointestinal, thoracic origin NCT - 02955069 |
Study to evaluate efficacy of PDR001 in patients with advanced or Metastatic non – functional Neuroendocrine tumors |
| Carcinoma of head and Neck 0364 - 16 | Study of Nivolumab in combination with Ipilimumab versus (Cetuximab+Cisplatin/Carboplatin+Fluorouracil) in Metastatic Squamous Cell Carcinoma |
| Carcinoma of head and Neck 0593-16 | Study of Pembrolizumab given Concomitantly with Chemoradiation Versus Chemoradiation alone |
| Advanced solid tumors (Vulvar or MSI-High) 0526-15 |
Clinical trial of Pembrolizumab(MK-3475) Evaluating Predictive Biomarkers |
| Advanced solid tumors 0315-16 | CSF-1R inhibitor LY3022855 in combination With Durvalumab |
| Melanoma 0448-16 | Study of Atezolizumab + Cobimetinib+Vemurafemib Versus Cobimetinib in untreated BRAFV600 mutation positive patients |
| Liver cancer 0428-14 | BSC as second line treatment in patients with hepatocellular Carcinoma and elevated Baseline Alpha-Fetoprotein (AFP) |
| Pancreatic cancer 289-16 | Study of Olaparib Monotherapy in patients with gBRCA mutated metastatic Pancreatic cancer |
| Stomach cancer 289-16 | CheckMate 577-Study of Nivolumab or Placebo in patients with Resected Lower Esophageal or Gastroesophageal junction cancer |
| Gastric cancer 0617-15 | TAS-102 Plus Best Supportive Care (BSC) versus Placebo Plus BSC in patients with metastatic Gastric cancer |
| Testicular cancer 0482-16 |
CheckMate 647-Nivolumab in Relapsed/Refractory central nervous system Lymphoma (PCNSL) or Testicular Lymphoma (PTL) |
| Glioblastoma 0487-15 | ABT-414 with concurrent Chemoradiation and Adjuvant Temozolomide in patients with Glioblastoma (GBM) with EGFR amplification |
| Lung cancer 0379-15 | IMpower010 MPDL3280A compared with BSC following adjuvant Cisplatin Chemotherapy in PD-L1 patients with non-small Cell lung cancer |
| Lung cancer 0319-16 | X-396 (Ensartinib) versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Non-Small Cell Lung cancer (NSCLC) |
| Mesothelioma 0015-16 | Nintedanib + Pemetrexed/Cisplatin followed by Nintedanib monotherapy versus Placebo with Pemetrexed/Cisplatin for patients with unresectable malignant pleural Mesothelioma |
| Ovarian cancer NCT-2470585 | Carboplatin/Paclitaxel with maintenance Veliparib (RAP inhibitor) in patients with Epithelial Ovarian, Fallopian tube, Peritoneal cancer |
| Ovarian cancer NCT-2470585 | Bay 17096- Radium 223 dichloride in combination with exemestane and everolimus versus placebo and exemestane and everolimus on HER2 negative hormone receptor positive breast cancer combination with Axitinib versus Sunitinib monotherapy in advanced renal cell Carcinoma |
| Breast cancer 0136-17 | Atezolizumab (Anti-Pd-L1 Antibody) in combination with Paclitaxel versus placebo with Paclitaxel for inoperable metastatic Triple Negative Breast cancer |
| Kidney cancer 0139-16 | JAVELIN Renal 101-Avelumab (msb0010718c) |
| Prostate cancer 0404-15 | JNJ-56021927 in high risk advanced Prostate cancer receiving radiation therapy |
| Bladder cancer 0351-16 | MK-3475-361/KEYNOTE-361A Pembrolizumab with combination of Chemotherapy versus Chemotherapy in patients with metastatic Urothelial Carcinoma at first line |
| AML 0049-13 | Treatment with BL-8040 in patients with reoccurring Acute myocardial leukemia (AML) |
| ALL 0490-13 | Treatment with Biblyntomombab in patients with reoccurring acute lymphocytic leukemia (ALL) |
| NHL 0268-13 | Ivrotiniv for chemotherapy treatment CHOP-R for Lymphoma patients of type DLBCL |
| Follicular Lymphoma 0349-14 | IPI-145 in combination with Ritoximab versus Ritoximan in previously treated Follicular Lymphoma patients |
| DLBCL 0544-14 | Treatment with Slinxor (KPT-330) in reaccuring Lymphoma of DLBCL type |
